Stereotactic Radiosurgery for Primary Central Nervous System Lymphoma: Results From the International Radiosurgery Research Foundation

View at publisher
Authors: Trent Kite, Rodney E. Wegner, Steven Karlovits, John Herbst, John Lister, Henry Knox, Joshua David Palmer, Eugene Yap, David Bailey, Mariana Dejuk, Sean S. Mahase, Brad E. Zacharia
+18 more Christian Amezquita-Contreras, Angel I. Blanco, Yoshua Esquenazi, Ronald E. Warnick, Keiss Douri, David Mathieu, Manjul Tripathi, Narendra Kumar, C. T. Lee, Huai-Che Yang, Anais C. M. A. de Moura, Jheremy S. Reyes, Bardia Hajkarimloo, Douglas Kondziolka, Ajay Niranjan, L. Dade Lunsford, Jason Sheehan, Matthew J. Shepard
Cited by: 1
References: 18

Abstract

BACKGROUND AND OBJECTIVES: Stereotactic radiosurgery (SRS) has been increasingly employed in the multimodal management of primary central nervous system lymphoma. Here, we evaluate the outcomes of SRS for the treatment of primary central nervous system lymphoma through a multicenter, international cohort study. METHODS: A multicenter, retrospective cohort study was conducted through the International Radiosurgery Research Foundation. Subgroups were defined according to treatment setting: up-front (primary treatment), boost (SRS after consolidative chemotherapy with or without whole-brain radiotherapy), and relapsed/refractory (recurrent/progressive disease after first-line therapy). The primary end point was local tumor control. Time-to-event analysis was conducted using the Kaplan-Meier method. Variables associated with local control were assessed using the Cox proportional hazard modeling. RESULTS: Fifty-four patients with 127 tumor sites were included in this analysis. Actuarial 12-month local and distant control rates for the entire cohort were 75.7% and 63.7%, respectively, with a median overall survival (OS) of 18 months (range: 1-176). Actuarial 12-month local control rates were significantly different at 95.6%, 78.3%, and 42.1% ( P < .0001) for the up-front, relapsed/refractory groups, and boost cohorts, respectively. OS across all cohorts were similar with 12-month OS rates of 55.2%, 51.3%, and 53.5% for the up-front, relapsed/refractory, and boost cohorts, respectively. Rates of radiation necrosis were 18.5%, 20.8%, 15.4%, and 11.8% for the entire cohort, relapsed/refractory, boost, and up-front cohorts, respectively. Diminished OS was significantly associated with treatment volumes >27 cm 3 (hazard ratio: 2.5, P = .04). CONCLUSION: SRS shows promising local tumor control rates for up-front and relapsed cohorts. Despite this, distant tumor progression limits total tumor control and may adversely affect OS.

Fields of Study & Subjects

CNS Lymphoma Diagnosis and Treatment Glioma Diagnosis and Treatment Brain Metastases and Treatment

Publication details

Journal / source
Neurosurgery
Publisher
Ovid Technologies (Wolters Kluwer Health)
Volume
99
Issue
4
Pages
820–829
Publication date
14 January 2026
Language
EN